Insider Selling: Fluidigm Co. (NASDAQ:FLDM) Insider Sells 134,487 Shares of Stock

Fluidigm Co. (NASDAQ:FLDM) insider Levin Easterly Partners Llc sold 134,487 shares of the business’s stock in a transaction that occurred on Wednesday, July 17th. The shares were sold at an average price of $11.32, for a total value of $1,522,392.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website.

Levin Easterly Partners Llc also recently made the following trade(s):

  • On Friday, July 19th, Levin Easterly Partners Llc sold 83,728 shares of Fluidigm stock. The shares were sold at an average price of $11.50, for a total value of $962,872.00.
  • On Friday, June 28th, Levin Easterly Partners Llc sold 157,349 shares of Fluidigm stock. The shares were sold at an average price of $12.30, for a total value of $1,935,392.70.
  • On Monday, July 1st, Levin Easterly Partners Llc sold 186,759 shares of Fluidigm stock. The shares were sold at an average price of $12.31, for a total value of $2,299,003.29.
  • On Tuesday, June 25th, Levin Easterly Partners Llc sold 217,148 shares of Fluidigm stock. The shares were sold at an average price of $12.28, for a total value of $2,666,577.44.

NASDAQ:FLDM opened at $11.49 on Monday. Fluidigm Co. has a 12-month low of $5.50 and a 12-month high of $14.90. The firm has a market cap of $793.04 million, a price-to-earnings ratio of -14.36 and a beta of 2.15. The company has a quick ratio of 2.86, a current ratio of 3.26 and a debt-to-equity ratio of 0.30. The firm’s 50 day moving average is $12.12.

Fluidigm (NASDAQ:FLDM) last released its quarterly earnings data on Thursday, May 2nd. The medical research company reported ($0.44) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.14) by ($0.30). Fluidigm had a negative net margin of 60.45% and a negative return on equity of 43.75%. The company had revenue of $30.10 million for the quarter, compared to analyst estimates of $29.18 million. The business’s quarterly revenue was up 19.4% on a year-over-year basis. As a group, sell-side analysts forecast that Fluidigm Co. will post -0.5 EPS for the current fiscal year.

A number of hedge funds have recently made changes to their positions in FLDM. FMR LLC acquired a new position in Fluidigm during the 1st quarter worth $24,188,000. RTW Investments LP acquired a new position in Fluidigm during the 4th quarter worth $7,622,000. ClariVest Asset Management LLC acquired a new position in Fluidigm during the 1st quarter worth $8,154,000. Millennium Management LLC boosted its position in Fluidigm by 171.1% during the 4th quarter. Millennium Management LLC now owns 932,996 shares of the medical research company’s stock worth $8,042,000 after acquiring an additional 588,862 shares during the period. Finally, Acadian Asset Management LLC boosted its position in Fluidigm by 57.0% during the 1st quarter. Acadian Asset Management LLC now owns 845,762 shares of the medical research company’s stock worth $11,238,000 after acquiring an additional 307,013 shares during the period. Institutional investors own 92.64% of the company’s stock.

A number of research analysts recently issued reports on the company. Zacks Investment Research upgraded HB Fuller from a “sell” rating to a “hold” rating in a research report on Wednesday, July 3rd. ValuEngine lowered Welbilt from a “hold” rating to a “sell” rating in a research report on Wednesday, June 12th. Piper Jaffray Companies boosted their price objective on Marvell Technology Group from $22.00 to $30.00 and gave the company an “overweight” rating in a research report on Friday, May 3rd. Finally, BidaskClub lowered Westport Fuel Systems from a “buy” rating to a “hold” rating in a research report on Friday. Three investment analysts have rated the stock with a hold rating and four have assigned a buy rating to the company. Fluidigm currently has a consensus rating of “Buy” and an average target price of $14.75.

Fluidigm Company Profile

Fluidigm Corporation creates, manufactures, and markets technologies and tools for life sciences research in the United States and Europe. It offers analytical systems comprising Helios, a CyTOF system, Hyperion imaging system, and Hyperion tissue imager; and assays and reagents, including Maxpar reagents and Maxpar human immune monitoring panel kit and workflow.

Read More: Bond

Insider Buying and Selling by Quarter for Fluidigm (NASDAQ:FLDM)

Receive News & Ratings for Fluidigm Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Fluidigm and related companies with MarketBeat.com's FREE daily email newsletter.